<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351351</url>
  </required_header>
  <id_info>
    <org_study_id>06-035</org_study_id>
    <nct_id>NCT00351351</nct_id>
  </id_info>
  <brief_title>Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy</brief_title>
  <official_title>Randomized Control Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana Kidney Stone Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana Kidney Stone Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous nephrolithotomy (PNL), in conjunction with intracorporeal lithotripsy, allows
      for the rapid removal of any kidney stone regardless of size. Currently, the choice of
      intracorporeal lithotripters includes ultrasonic, pneumatic, and combined
      ultrasonic/pneumatic energy sources. Recently, a novel dual probe design as been introduced
      by Cybersonics of Erie, Pennsylvania. This dual probe intracorporeal lithotrite is called the
      Cyberwand, and is composed of a fixed inner probe vibrating at an ultrasonic frequency with
      an outer probe vibrating at about 1,000 Hz. As this new design has the potential to
      revolutionize intracorporeal lithotripsy, we intend to compare this novel technology to
      currently available lithotripsy technology in a randomized clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous nephrolithotomy (PNL) is used to remove large and complex stones from the upper
      urinary tract. Intracorporeal lithotripsy is an integral part of PNL. Commercially available
      intracorporeal lithotripsy modalities include ultrasonic, pneumatic, and combined ultrasonic
      and pneumatic models. Each modality has its inherent advantages and disadvantages. Ultrasonic
      lithotrites are capable of fragmenting stones while concomitantly suctioning out fragments.
      Unfortunately some stones are hard enough to resist fragmentation from ultrasonic
      lithotripsy. Pneumatic lithotrites are able to fragment all stones regardless of hardness,
      but this modality is unable to suction out stone pieces at the same time fragmentation is
      occurring. The newest lithotrite which combines both ultrasonic and pneumatic components is
      capable of fragmenting any stone, but also has some inherent limitations. The handpiece of
      the lithotripsy device is somewhat cumbersome, the suction component can clog, and the device
      has overheated at the maximal settings (Kuo et al). Current intracorporeal lithotrites, while
      functional, can certainly be improved.

      Recently, a novel dual probe design has been introduced by Cybersonics of Erie, PA. This dual
      probe intracorporeal lithotrite is called the Cyberwand and is composed of a fixed inner
      probe vibrating at an ultrasonic frequency with an outer probe vibrating at about 1,000 Hz.
      As this new design has the potential to revolutionalize intracorporeal lithotripsy, we intend
      to compare this novel technology to currently available lithotripsy technology in a
      randomized clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney Stone Clearance Rate</measure>
    <time_frame>6 months</time_frame>
    <description>stone clearance rate calculated in mm^2/min per protocol specification</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyberwand</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Currently available lithotripsy technology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cyberwand</intervention_name>
    <description>FDA approved - dual probe intracorporeal lithotrite</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>single probe ultrasonic</intervention_name>
    <description>FDA-approved - single probe ultrasonic</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient of Methodist Urology in Indianapolis, IN

          -  Undergoing percutaneous nephrolithotomy for calculi greater than 2 cm

          -  Age 18 years or older

          -  Stone easily visible/measurable on kidney, ureters and bladder (KUB) or computed
             tomography (CT) scan preoperatively

        Exclusion Criteria:

          -  Radiolucent stones

          -  Size of largest stone less than 2 cm

          -  Pregnancy

          -  Inability to give informed consent

          -  Multiple percutaneous access anticipated

          -  Active urinary tract infection

          -  Recent (within last 3 months) extracorporeal shock wave lithotripsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James E. Lingeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Dept. of Urology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John's Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario - St. Joseph's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kuo RL, Paterson RF, Siqueira TM Jr, Evan AP, McAteer JA, Williams JC Jr, Lingeman JE. In vitro assessment of lithoclast ultra intracorporeal lithotripter. J Endourol. 2004 Mar;18(2):153-6.</citation>
    <PMID>15072622</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>January 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2013</results_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Stones</keyword>
  <keyword>Renal Calculi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients undergoing percutaneous nephrolithotomy with a target stone size greater than 2cm</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyberwand</title>
          <description>Cyberwand
Cyberwand : FDA approved - dual probe intracorporeal lithotrite</description>
        </group>
        <group group_id="P2">
          <title>Currently Available Lithotripsy Technology</title>
          <description>Currently available lithotripsy technology
single probe ultrasonic : FDA-approved - single probe ultrasonic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>surgical access pbs; device issues</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyberwand</title>
          <description>Cyberwand
Cyberwand : FDA approved - dual probe intracorporeal lithotrite</description>
        </group>
        <group group_id="B2">
          <title>Currently Available Lithotripsy Techology</title>
          <description>Currently available lithotripsy technology
single probe ultrasonic : FDA-approved - single probe ultrasonic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kidney Stone Clearance Rate</title>
        <description>stone clearance rate calculated in mm^2/min per protocol specification</description>
        <time_frame>6 months</time_frame>
        <population>Sample size calculations were performed using a two-sided Student’s t-test with a power of 90% and a significance level of α = 0.05</population>
        <group_list>
          <group group_id="O1">
            <title>Cyberwand</title>
            <description>Cyberwand
Cyberwand : FDA approved - dual probe intracorporeal lithotrite</description>
          </group>
          <group group_id="O2">
            <title>Currently Available Lithotripsy Techology</title>
            <description>Currently available lithotripsy technology
single probe ultrasonic : FDA-approved - single probe ultrasonic</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Stone Clearance Rate</title>
          <description>stone clearance rate calculated in mm^2/min per protocol specification</description>
          <population>Sample size calculations were performed using a two-sided Student’s t-test with a power of 90% and a significance level of α = 0.05</population>
          <units>mm^2/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" lower_limit="6.1" upper_limit="222.69"/>
                    <measurement group_id="O2" value="75.8" lower_limit="9.16" upper_limit="551.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cyberwand</title>
          <description>Cyberwand
Cyberwand : FDA approved - dual probe intracorporeal lithotrite</description>
        </group>
        <group group_id="E2">
          <title>Currently Available Lithotripsy Technology</title>
          <description>Currently available lithotripsy technology
single probe ultrasonic : FDA-approved - single probe ultrasonic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>persistent flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>perinephric haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>discharged home with nephrostomy tube</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>respiratory difficulty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Multiple surgeons were involved,thus subtle differences in PCNL technique existed between sites. Some surgeons may have defined the stone removal time differently.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Lingeman, MD</name_or_title>
      <organization>IU Health Methodist Hospital</organization>
      <phone>317-962-0870</phone>
      <email>lrawlings@iuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

